AstraZeneca CEO £2.3m Bonus Hike Sparks Shareholder Row

Pascal Soriot, as AstraZeneca Executive Director and CEO, during US Senate Finance Committee hearing on drug prices, graphic element on gray Amid mounting scrutiny of AstraZeneca's ( AZ.L ) COVID-19 vaccine, the company's CEO is facing pushback from shareholders over a potential big bump in bonuses. Pascal Soriot is in line for a windfall of between £2.3m ($3.2m) and £12m — a sum that could rise in line with AstraZeneca's share price...
Login to comment.